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Micrognathia, glossoptosis, and cleft palate comprise one of the most commonmalformation sequences, Robin sequence. It is a compo-
nent of the TARP syndrome, talipes equinovarus, atrial septal defect, Robin sequence, and persistent left superior vena cava. This disorder
is X-linked and severe, with apparently 100% pre- or postnatal lethality in affected males. Here we characterize a second family with
TARP syndrome, conﬁrm linkage to Xp11.23-q13.3, perform massively parallel sequencing of X chromosome exons, ﬁlter the results
via a number of criteria including the linkage region, use a unique algorithm to characterize sequence changes, and show that TARP
syndrome is caused by mutations in the RBM10 gene, which encodes RNA binding motif 10. We further show that this previously
uncharacterized gene is expressed inmidgestationmouse embryos in the branchial arches and limbs, consistent with the human pheno-
type. We conclude that massively parallel sequencing is useful to characterize large candidate linkage intervals and that it can be used
successfully to allow identiﬁcation of disease-causing gene mutations.Introduction
Advances in genomic technologies can markedly speed
the analysis of genetic contributions to disease and make
once-intractable questions tractable. The technique of
massively parallel sequencing with exon capture allows
rapid assessment of mutations that cause human
diseases.1,2 The syndrome we have chosen to study with
this new technology is an X-linked pleiotropic develop-
mental anomaly syndrome (MIM 311900) comprising mi-
crognathia, glossoptosis, and cleft palate (currently
described as Robin sequence), persistent left superior
vena cava, atrial septal defect, and talipes equinovarus,
which was originally called ‘‘Robin’s syndrome’’ by Gorlin
et al.3 Subsequently, this disorder was designated as TARP
syndrome based on the acronym formed by talipes equino-
varus, atrial septal defect, Robin sequence, and persistence
of the left superior vena cava (to avoid confusion of Robin
sequence and ‘‘Robin’s syndrome’’). Linkage analysis of the
family originally evaluated by Gorlin et al.3 conﬁrmed the
X-linked inheritance by mapping the locus to Xp11.23-
q13.3.4 Although this mapping conﬁrmed the inheritance
pattern and narrowed the candidate gene list, the region
was nearly 28 Mb (from 46.42 Mb to 74.04 Mb; genome
build 36) and contained more than 200 genes or tran-
scripts, including several complex gene families of G
antigen transcripts. Thus, the task of interrogating all of
these genes for sequence variants and validating the
variants was daunting.
Here we report the identiﬁcation of the second family
manifesting this syndrome, describe the phenotype in
three affected males, show that the second family has
linkage that is consistent with that of the initial family,1National Human Genome Research Institute (NHGRI), National Institutes of H
Center, Bethesda, MD 20892-4472, USA; 3Prenatal Diagnosis and Medical Gen
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The Amedescribe our use of chromosome X exon target capture
and massively parallel (so-called ‘‘next-gen’’) sequencing
to identify RBM10 (MIM 300080) mutations in the two
families, and show that the murine Rbm10 gene is ex-
pressed in midgestation embryos in a pattern consistent
with the human phenotype.Materials and Methods
Target Selection and Sequencing
DNA isolation, genotyping, and haplotype analysis were per-
formed as previously described.4 To sequence genes, we used solu-
tion hybridization selection (SureSelect, Agilent) to generate a
single-end sequencing library according to the manufacturer’s
directions (Illumina). For the purpose of this project, the exon
targetsweredeﬁnedas all codingDNAsequence (UCSC)geneexons
between positions 2,710,679 bp and 154,500,000 bp, which is
fromXG (MIM314700) toTMLHE (MIM300777), inclusive,human
genome build 36 (hg18). The target sequence was 2,784,426 bp,
and the oligonucleotide library was designed to target 2,264,175
bp of this (81.3%). Brieﬂy, 3 mg of genomic DNA was sheared via
acoustic fragmentation (model S2, Covaris) with the following
parameters: duty cycle, 10%; intensity, 5; cycle burst, 200; time,
180 s; set mode frequency, sweeping; temperature, 4C. The DNA
was subjected to end repair and adaptor ligation (NEBNext DNA
Sample Prep Reagent Set 1, New England Biolabs). Size selection
of 200–300 bp fragments was performed by using electrophoresis
(4% NuSieve GTG gel, Lonza Group). The prepped library was
ampliﬁedwithprimers 1.1 and2.1 (Illumina). The ampliﬁed library
was hybridized to biotinylated RNA library baits (Agilent), and
targeted sequences were puriﬁed with magnetic beads (Dynal
M-280 streptavidin, Invitrogen). Puriﬁed target sequences were
ampliﬁed with proprietary PCR primers (Agilent) and DNA poly-
merase (Herculase II fusion, Stratagene).ealth (NIH), Bethesda, MD 20892-4472, USA; 2NIH Intramural Sequencing
etics Program, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
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Interpretation of Coding Variations
To predict possible deleterious effects of coding changes on the
native state of the protein, we developed novel software to predict
the deviation from the ‘‘normal’’ function relative to the human
reference sequence and associated UCSC known gene models
(hg18). This software computes the consequence of the change
to the sequence and predicts whether the nucleotide variation
leads to a silent, missense, nonsense, canonical splice-site, or
frameshift change. CDPred, a module within the coding analysis
software, is an algorithm that scores amino acid variants on the
basis of evolutionary conservation in conserved protein coding
domains. CDPred assigns all nonsense, splice-site, and frameshift
changes in a protein the most damaging score (30), under the
hypothesis that these variants lead to truncated protein products
or nonsense-mediated mRNA decay, both of which can be equiv-
alent to a null protein. This algorithm also predicts whether a
missense change would be deleterious to the function of the
protein, based on a log-likelihood score computed from a posi-
tion-speciﬁc scoringmatrix of the best-aligning protein-conserved
domain model to the query protein. For a given missense change
(relative to the reference codon), the scores are in a range of þ20
to 20.
The CDPred algorithm is initialized with a reference protein
sequence and the variant (missense or nonsense) relative to the
reference. An alignment of the reference protein sequence to a
database of protein domain models (position-speciﬁc scoring
matrices) was computed with RPS-BLAST (parameters: –e
0.00001 and –F T). Sequence alignments with greater than 80%
overlap of the length of the model with an E value less than
1e-5 were considered to be signiﬁcant. The delta log-likelihood
scores were computed as the difference in position-speciﬁc scores
of the variant amino acid and the reference amino acid. The lower
or more negative the score, the more deleterious was the predicted
change. Positive scores above 3 may also be potentially damaging,
but a strongly positive score generally results from a situation in
which the normal human amino acid at a position is different
frommany or all other aligned species over a domain and inwhich
the variant allele is closer to the ancestral form. For example, if an
individual had the ancestral form of the FOXP2 gene (MIM
605317), that individual would potentially exhibit loss of speech;
however, the delta score for the amino acid positions that are
unique to all other humans would be positive because that
individual more closely resembles the ancestral form. The CDPred
software is available for evaluation and implementation at the
website listed in the Web Resources section of the paper.Mutation Conﬁrmation and Segregation Studies
PCR ampliﬁcation and Sanger sequencing of DNA samples to
conﬁrm themutations and cosegregation were performed as previ-
ously described.5 PCR primer sequences are available upon
request. Mutation numbering was performed according to Human
Gene Variation Society nomenclature with reference sequence
NM_005676.3. Human studies were performed according to an
approved human subjects research protocol of the NHGRI institu-
tional review board, and informed consent was obtained.In Situ Analysis
C57BL/6J mouse embryos were ﬁxed overnight in 4% paraformal-
dehyde in PBS. Reverse-transcribed digoxigenin-conjugated
probes were made from PCR products with polymerase binding
site linkers. The following DNA source was used for probe744 The American Journal of Human Genetics 86, 743–748, May 14,synthesis: Rbm10, reverse transcription PCR from C57BL/6J skin
total RNA (Rbm10-F-T3- GCGCGAATTAACCCTCACTAAAGGGC
GGGATGGATTAGGCAGTGAC; Rbm10-R-T7-GCGCGTAATACG
ACTCACTATAGGGACAAAAGGAACATGATTTGAG). In situ hy-
bridizations were performed by using published protocols6 with
the following modiﬁcations. After probe hybridization, ribonu-
clease A digestion was omitted, and tris-buffered saline was used
in place of PBS. BM-purple substrate (Roche, Molecular Biochemi-
cals) was used in place of 5-bromo-4-chloro-3-indolyl phosphate
and nitroblue tetrazolium.7 Multiple embryos were evaluated at
each stage of development analyzed: E9.5 (n ¼ 6), E10.5 (n ¼ 5),
and E11.5 (n ¼ 4). Murine procedures were performed in accor-
dance with NIH guidelines and under NHGRI mouse protocol
G94-7.Clinical Reports
Individual III-3 (Figure 1) was born at 32 weeks gestation to a
22-year-old gravida 4 para 2–3 abortus 1 mother. The pregnancy
was complicated by oligohydramnios and premature rupture of
the membranes. Delivery was breech. Although a fetal heartbeat
was noted on examination within 2 min prior to delivery, APGAR
scores were 0 at 1, 5, and 10 min. The baby boy died at 5 min of
age. Upon postmortem examination, his weight was 1335 g and
his crown heel length was 41 cm (both appropriate for gestational
age). External examination showed apparently low-set ears, micro-
gnathia, and a large cleft of the hard and soft palate. The hands
were broad, with ulnar deviation. Bilateral talipes equinovarus
and rocker bottom feet were present. The right testicle was unde-
scended. Upon internal examination, he was found to have a large
atrial septal defect, and his lung showed an underdeveloped third
lobe with overall marked underdevelopment of alveoli. A Meckel
diverticulum was present. Radiography showed a severely under-
developed mandible. Microscopic description showed extrame-
dullary hematopoiesis of the liver. Standard resolution karyotype
was reported as normal, 46,XY.
Individual III-9 was born at 37.5 weeks gestation to a 26-year-old
gravida 1 para 1 mother. The prenatal course was notable for
intrauterine growth retardation late in pregnancy. At birth, the
baby boy weighed 2090 g (~tenth centile) and his length was
46 cm (appropriate for gestational age). He was apneic, hypotonic,
and cyanotic post delivery. He had micrognathia, cleft palate,
glossoptosis, and hyaline membrane disease. He developed
seizures at 24 hr. Head ultrasound showed basal ganglia hemor-
rhages and subdural hematoma. He was intubated, but he died at
8 days of age with liver failure, kidney failure, hyaline membrane
disease, athetoid movements, and seizures. Autopsy was declined.
Individual III-15 was born at 28 weeks gestation to a 23-year-old
gravida 2 para 1–2 mother. Few clinical details are available about
this affected baby boy. At birth, he was found to have multiple
anomalies including cleft palate (Robin sequence), possible
cardiac defects, and bilateral talipes equinovarus. He died of his
multiple congenital anomalies.Results
Linkage analysis of the original family identiﬁed an 11 cM
region in Xp11.23-q13.3 with a peak LOD score of 2.75 at
marker DXS1039.4 The borders of the region were deﬁned
by recombinantmarkers atDXS1003 andDXS8092. Haplo-
type analysis was performed in family 2 with these three2010
Figure 1. Pedigree of TARP Syndrome Family 2
The three affected male individuals are shown with darkened symbols. Obligate female carriers have a dot within their symbol. Nine
family members were genotyped for the c.1235G>A mutation; their status is indicated by the þ (wild-type) or m (mutant) designations
below each pedigree symbol. Also shown are Sanger electropherograms of the two mutations; on the left is the nonsense mutation
c.1235G>A found in family 2 below the control sequence, and on the right is the insertion mutation c.1893_1894insA found in family
1, again below the control sequence.
Table 1. The Number of Genes with One or More Variants
Following Each Filtering Criterion
All X Exons1 Linkage Region
Family 1 Family 2 Family 1 Family 2
Total substitutions 360 330 85 76
Heterozygous 271 229 54 54
Nonsynonymous 71 65 14 14
Not in dbSNP 14 16 5 4
Not in three controls 11 11 3 3
Nonsense 0 1 0 1
Total indels 53 47 9 7
Nonsynonymous 8 7 2 1
Not in dbSNP 3 2 1 0
Not in three controls 1 1 1 0
Frameshifting 1 0 1 0
1 Refers to targetable exons between XG and TMLHE.markers and additional markers both within and outside of
the region (DXS8054, DXS1208, DXS7132, and DXS6800).
Haplotypes were consistent with affection or carrier status
in all individuals tested, and there were no recombinations
in family 2 that narrowed the region deﬁned by family 1
(data not shown). The linked short tandem repeat poly-
morphism haplotype in the two families was distinct,
suggesting that the mutations in the two families were
likely to be distinct.
The target-selected DNA libraries from one female
heterozygote from each of the two families (females were
used for optimal DNA quantity and quality) were se-
quenced on one lane each of a sequencing instrument
(Illumina GAII) in single-end 36 bp conﬁguration, which
yielded 20,262,045; 18,775,942 reads (family 1; family 2)
or 729,433,620; 675,933,912 bp of total sequence. Of
this sequence, 43.8%; 45.2% could be uniquely aligned
to the targeted exons. This aligned sequence yielded a gross
overall coverage of 1153; 1103 of the target. The capture
efﬁciency varied across the targets with 2,239,228;
2,234,963 bp (80.5%) of the target with R13 coverage,
2,136,202; 2,128,057 bp (76.5%) with R103 coverage,
and 2,071,297; 2,059,012 bp (74.1%) with R203
coverage. The most probable genotype variant-calling soft-
ware (J.K.T., N.F.H., J.C.M., and L.G.B. et al., unpublished
data) was able to make high-conﬁdence genotype calls
on 1,956,070; 1,941,688 bp of this sequence (70.0%).
We ﬁltered the results for variants in genes on the basis
of several attributes that we reasoned were appropriateThe Amefor this disorder (Table 1). Heterozygosity was used because
the test subjects were both unaffected female carriers for an
X-linked trait. We reasoned that the variant should be
severe because it caused a lethal phenotype in hemizygous
males, so we ﬁltered for nonsynonymous and stop alleles.
Similarly, we also scanned the sequences for insertion or
deletion variants, reasoning that most of these wouldrican Journal of Human Genetics 86, 743–748, May 14, 2010 745
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Figure 2. Cartoon of the RBM10 Gene Structure, Alternative
Splicing, Conserved Domains, and Mutations Found in Two
Families with TARP Syndrome
For clarity, the width of the rectangles is the same for all exons and
is therefore not proportional to the actual length of the exons. The
50 and 30 UTRs are shown as rectangles with reduced vertical
height. The gene has two mRNA isoforms: variant 1, which
includes exon 4, and variant 2, which does not. Note that all other
exons are believed to be constitutively spliced into both isoforms,
so splicing lines are not shown for those exons. The portions of the
gene that encode for the four recognized conserved domains are
shown (two RRM, RNA recognition motif znfRBP, a zinc ﬁnger
Ran binding protein, and a G-patch domain). Finally, the two
independent mutations found in families 1 and 2 are shown.cause frameshifting, null alleles. The criterion of novelty
was applied in two ways. First, we ﬁltered for variants not
present in dbSNP, reasoning that a variant causing a rare
phenotype should not be common. Second, we ﬁltered
for the absence of a sequence variant in three control
DNA samples. The controls included two samples from
males with syndromic microphthalmia and a single
sample from a female parent of a child with a previously
uncharacterized X-linked lethal disorder. We also applied
a ﬁlter that bounded the variants genomically within the
deﬁned linkage interval from the original family, which
was conﬁrmed in family 2.
The initial analysis focused on single base pair substitu-
tions, which, with the application of the heterozygosity þ
nonsynonymous þ nonsense þ novelty ﬁlters (Table 1),
showed a single nonsense mutation, c.1235G>A in
RBM10 (RNA binding motif 10), which predicts
p.Trp412X in family 2 (Figure 1, lower left panels; Figure 2).
No other nonsense mutations were identiﬁed in either
family with this alignment and these ﬁlters. A second
analysis for small deletions and insertions was performed
with the following ﬁlters: nonsynonymous þ novelty þ
frameshifting. This allowed identiﬁcation of a single muta-
tion in family 1, which was c.1893_1894insA in RBM10,
which predicts p.Pro632ThrfsX41 (Figure 1, lower right
panels; Figure 2). Each RBM10 variant was conﬁrmed by
PCR ampliﬁcation and Sanger sequencing (Figure 1,
bottom) in multiple individuals within the respective
family, and mutation status segregated with known carrier
status in all individuals (cosegregation is shown for family
2 in Figure 1; cosegregation for family 1 is not shown). We
concluded that these were causative variants on the basis
of the co-occurrence of a nonsense and a frameshift muta-
tion in the same gene in two families with a highly similar
and extremely rare phenotype.
Because the RBM10 gene product was poorly character-
ized and mutations had not been described with any746 The American Journal of Human Genetics 86, 743–748, May 14,abnormal phenotype in humans or in animal models, we
set out to characterize the expression of this gene in midg-
estation mouse embryos. The orthologous murine Rbm10
isoform 1 gene product is 96% identical to the human
protein. We isolated an Rbm10 antisense probe from the
mouse sequence via RT-PCR of whole mouse RNA isolated
from embryonic day E16.5 skin. Whole-mount in situ
expression analysis of the murine Rbm10 gene at E9.5
and E10.5 of development showed a similar pattern of
expression, with the most robust staining observed in the
ﬁrst branchial arch (which gives rise to the mandible),
second branchial arch, developing limb buds, and tailbud
(Figure 3). Robust expression remained for E11.5 embryos
in both the limb and tail bud regions, whereas expression
in branchial arches one and two decreased at this stage
(data not shown). This pattern of expression correlated
well with the human malformations observed in TARP
syndrome, which include severe micrognathia and limb
defects.Discussion
Here we show that the use of targeted exon capture with
ﬁlters that included a genomic delimitation deﬁned by a
linkage region, the zygosity state, novelty, a severe delete-
rious mutation prediction, and a common mutation
among two affected families can identify a gene mutated
in a rare disorder. This approach was efﬁcient and less
time consuming compared with what would be required
for PCR ampliﬁcation and Sanger sequencing of the
approximately 200 genes within the ~28 Mb candidate
interval. These data show two rare variants in RBM10,
one in each of two families with a highly similar, rare,
pleiotropic multiple congenital anomaly syndrome. We
suggest that the delineation of nonsense or frameshift
mutations in each of two families with a rare disorder is
unlikely by chance alone. A simple estimate of the proba-
bility of ﬁnding these variants in the same gene in two
patients in a candidate gene region of 200 genes is 1/200,
or 0.005. Notably, nonsense or stop variants in RBM10
were not found in the recent report of 208 patients with
mental retardation.8 In addition, the mouse expression
data showed a striking correlation with the phenotypic
manifestations in the human disorder. Finally, the variants
cosegregated with the carrier status of the females in both
families. We conclude that these data show that nonsense
or null mutations in RBM10 cause syndromic Robin
sequence, or TARP syndrome.
The only previous report of RBM10 and human pheno-
types that we identiﬁed was a case report of a girl with an
X;15 translocation with hypertelorism, a small face, high
forehead, small, low-set ears, ulnar deviation of the hands,
agenesis of the corpus callosum, and a hypoplastic ﬁfth toe
and metatarsal.9 This X;15 translocation breakpoint was
near RBM10, although it was not determined whether
the expression of RBM10 was altered by this translocation.2010
Figure 3. Expression of the Murine
Ortholog Rbm10 inMidgestation Embryos
(A) In situ hybridization of a probe to
murine Rbm10 in a wild-type E10.5 mouse
embryo. There is expression of the tran-
script primarily in branchial arches 1 and
2. There is some expression in the limb
(L), in a region that partially overlaps the
apical ectodermal ridge.
(B) Expression of Rbm10 in an E9.5 mouse
embryo. At this stage, the expression is
slightly less strong in the second branchial
arch and limb but is strong in the ﬁrst
branchial arch. Expression was also noted
in the tail (T) at both stages.This girl and the boys from families 1 and 2 with TARP did
not have extensive phenotypic similarity; thus, it is
unlikely that this translocation mediated its phenotypic
effects primarily through disruption or dysregulation of
RBM10.
The RBM10 gene and its 930 amino acid protein product
is a member of the RNA binding motif (RBM) gene family.
The RBM gene family is large, but mutations in only a few
of the family members cause recognized human disorders,
including dilated cardiomyopathy10 (MIM 613172), which
is caused by mutations in RBM20 (MIM 613171), and
alopecia, neurologic defects, and endocrinopathy syn-
drome11 (MIM 612079), which are caused by mutations
in RBM28 (MIM 612074). A number of RBM genes have
been shown to be important for RNA processing, RNA
splicing, apoptosis, and other diverse biologic roles.12
RBM10 has been shown to undergo typical X chromosome
inactivation.13–15 RBM10 is predicted to include a zinc
ﬁnger motif, a G patch, and two RNA recognition motif
(RRM) domains (Figure 2). This architecture is found in a
variety of RNA binding proteins, including different
heterogeneous nuclear ribonucleoproteins (RNPs), protein
components of small nuclear RNPs, and those implicated
in the regulation of alternative splicing. A typical RRM
domain has two RNA or DNA binding sites and one RRM
dimerization site.
The RBM10 gene has two known alternative splice
forms. Variant 1 codes for a 930 amino acid protein
(NM_005676, 23 coding exons), and variant 2 codes for
an 852 amino acid protein (NM_152856, 22 coding exons).
The nonsense change (p.Trp412X in the long form) would
truncate the protein just after the end of the second RRM
motif, which may destabilize the overall structure of the
RBM10 protein. The frameshift (p.Pro632ThrfsX41) would
also affect the last third of the protein. Alternatively, these
truncating mutations may induce nonsense-mediated
mRNA decay. In either case, the loss of function of
RBM10 in TARP syndrome demonstrates that this gene is
critical for normal mammalian development. Further
elucidation of the role of this gene in early embryogenesis
will lead to a better understanding of congenital anomalies
that affect the face, heart, and limbs.The AmeThe ﬁltering of the sequence data shows that the RBM10
gene could have been identiﬁed without linkage data,
because the two RBM10 mutations were the only variants
that met all of the ﬁltering criteria for the entire targeted
set of exons in these two families. We recognize that the
determination of appropriate ﬁltering criteria is subjective
and that the outcome may be difﬁcult to predict. For
example, our criterion that themutations should be frame-
shifting or nonsense would not hold for all X-linked male
lethal disorders. Our overall approach was to begin with
stringent or conservative ﬁlters and relax them in succes-
sive analyses in an attempt to identify the mutated gene.
We were fortunate that the ﬁrst ﬁltering screen was
successful, but we recognize that this will not always be
the case. As noted in the methods section, this sequence
experiment included ﬁve samples. The others were three
patients who, among them, had two disorders distinct
from TARP. We believe that we have identiﬁed the causa-
tive mutations in one of these two disorders by use of
the same ﬁltering used to identify the TARP mutations,
but the other has failed to identify a causative gene muta-
tion (data not shown). Much more data on similar projects
will need to be generated to develop optimal approaches to
ﬁltering.
Another potential cause of a failure to identify causative
mutations by exon capture is oligonucleotide design and
sequencing coverage. This implementation of solution
hybridization exon targeting included oligonucleotide
designs for just over 80% of the exonic base pairs. After
generating >1003 of aligned sequence coverage for each
sample, we had adequate coverage (R10 quality base score
depth) for detection of heterozygous changes in 80% of
the base pairs of RBM10. This would suggest that for any
pair of samples from patients with TARP syndrome, where
each sample has one causative mutation in each of two
distinct targets, there is about a 60%–65% chance that
the mutations in both will be detected. In addition, non-
exonic variants, synonymous variants that may affect
splice enhancers, and other types of causative mutations
are likely to be challenging to detect by exon targeting.
Therefore, early successes in gene identiﬁcation by target
selection will not be representative of all disorders, and itrican Journal of Human Genetics 86, 743–748, May 14, 2010 747
will be important to develop new approaches to address
these challenges.Acknowledgments
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